NASDAQ$GOCO

GoHealth Inc · Q2 2025 earnings

Q2 2025 earnings · · Before market open · Investor relations

Briefing

GoHealth reported Q2 2025, revenue of $94M, a net loss of $116M, diluted EPS of $-5.10.

For Q2 2025, GoHealth reported Revenue was $94M; net loss was $116M; diluted EPS was $-5.10. Management discusses operating trends, liquidity, capital priorities, and sector risks in the quarterly filing.

  • Revenue $94M.
  • Net loss $116M.
  • Diluted EPS $-5.10.
  • GoHealth MD&A highlights liquidity, capital, and core operating trends.
  • Macro and competitive factors shape year-over-year comparisons.

Headline financials

Total Revenue

$94M

Previous: $106M-11.2%
EPS (adj)

-$5.10

Previous: -$2.70-88.9%
Adjusted EBITDA Margin

-12.0%

Previous: -11.6%-3.4%
EBITDA

-$73.2M

Previous: -$15M-389.3%
Adjusted EBITDA

-$11.3M

Previous: -$12.3M+8.2%
Direct Op. Cost of Submission

$86.4M

Previous: $97.6M-11.4%
Sales/Direct Cost of Submission

1.1

Previous: 1.1+0.0%
Sales per Submission

$657.00

Previous: $690.00-4.8%
Direct Operating Cost per Submission

$613.00

Previous: $641.00-4.4%
Submissions

141.0K

Previous: 152.4K-7.5%
Net Income

-$54.3M

Previous: -$26M-108.8%
Operating Income

-$99.4M

Previous: -$40.6M-144.7%

Revenue & EPS history

GoHealth · Revenue · Quarterly

$94M

Q2 2025-11.2%vs Q2 2024
Beat estimate in 5 of 14 quarters(36%)
ActualEstimate

Revenue by segment

GoHealth · $11.9M total across 4 segments · Q1 2026

  • Medicare Agency Revenue
    $9.8M
  • Other Non-Agency Revenue
    $1.76M
  • Medicare Non-Agency Revenue
    $200K
  • Other Agency Revenue
    $155K

Forward guidance

GoHealth discusses outlook, capital allocation, and key risks for upcoming periods in the filing.

Tailwinds

  • GoHealth cites execution on strategic and operating priorities.
  • Liquidity supports ongoing operations and investment.
  • Management monitors demand and cost trends.

Headwinds

  • Macro uncertainty may pressure volumes or margins.
  • Competitive dynamics in core markets.
  • One-time items can affect quarter-to-quarter comparability.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q2 2025

Historical avgQ2 2025

-7.7%

Avg return

Earnings day

-9.7%

Avg return

5 days after

-6.6%

Avg return

30 days after

26%

6 / 23 earnings

Positive

+32.2%

Q1 2023

Best reaction

-45.5%

Q2 2021

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.5%-23.4%
Q3 2025-24.4%-32.0%-12.8%
Q2 2025-9.0%-7.6%-23.8%
Q1 2025-0.6%-17.4%-21.4%
Q4 2024-14.4%-14.9%-32.8%
Q3 2024-6.6%-0.4%-15.4%
Q2 2024-21.4%-28.3%-34.0%
Q1 2024-8.0%-11.1%+2.2%
Q4 2023-13.0%-25.7%-27.0%
Q3 2023+2.3%+6.7%+7.4%
Q2 2023+6.8%+6.3%-17.2%
Q1 2023+32.2%+44.8%+99.5%
Q4 2022-19.9%-6.2%-18.5%
Q3 2022-16.7%-9.4%+95.3%
Q2 2022-31.5%-43.3%-57.0%
Q1 2022+11.1%+4.9%+6.5%
Q4 2021+23.7%+37.7%-9.8%
Q3 2021+1.1%-4.7%-18.1%
Q2 2021-45.5%-42.2%-34.7%
Q1 2021-2.7%-5.6%-4.0%
Q4 2020-14.9%-16.9%-4.1%
Q3 2020-14.9%-15.1%+1.8%
Q2 2020-10.5%-18.5%-27.1%
Q1 2020
Q4 2019
Q2 2019
Q1 2019

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro